ProCE Banner Activity

New Directions in Treating Peripheral T-Cell Lymphomas: Expert Guidance and Practical Case Discussions

Case Challenge
Multimedia
Watch this CME-certified, on-demand Webcast of a CCO symposium at ASH 2019, as a panel of expert faculty discusses the latest data regarding the treatment of patients with PTCL.

Released: January 27, 2020

Expiration: January 25, 2021

No longer available for credit.

Share

Faculty

Francine Foss

Francine Foss, MD

Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Steven M. Horwitz

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Barbara Pro

Barbara Pro, MD

Professor of Medical Oncology
Chief of Lymphoma Section
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Seagen

Takeda Oncology

Learning Objectives

  • Understand how unique agent mechanisms of action can specifically target PTCL subtypes
  • Assess molecular and phenotypic biomarkers as part of the diagnosis of PTCL and individualization of therapy decisions
  • Plan frontline treatment strategies for PTCL based on available clinical data along with expert and guideline recommendations
  • Integrate available and promising therapeutic options in patients with relapsed/refractory PTCL
  • Refer eligible patients with PTCL to clinical trials of new agents and combination therapeutic strategies

Faculty Disclosure

Primary Author

Francine Foss, MD

Professor of Medical Oncology
Yale Cancer Center
Yale University School of Medicine
New Haven, Connecticut

Francine Foss, MD, has disclosed that she has received consulting fees from Mallinckrodt and Miragen and fees for non-CME/CE services from Celgene, Seattle Genetics, and Spectrum.

Steven M. Horwitz, MD

Assistant Attending Physician, Lymphoma Service
Department of Medicine
Memorial Sloan-Kettering Cancer Center
New York, New York

Steven M. Horwitz, MD, has disclosed that he has received consulting fees from Affirmed, Astex, Celgene, Kyowa Hakko Kirin, Merck, Seattle Genetics, Takeda, and Verastem and funds for research support from ADC Therapeutics, Celgene, Corvus, Daiichi Sankyo, Forty Seven, Kyowa Hakko Kirin, Portola, Seattle Genetics, Takeda, Trillium, and Verastem.

Barbara Pro, MD

Professor of Medical Oncology
Chief of Lymphoma Section
Division of Hematologic Malignancies and Hematopoietic Stem Cell Transplantation
Kimmel Cancer Center
Thomas Jefferson University
Philadelphia, Pennsylvania

Barbara Pro, MD, has disclosed that she has received consulting fees from ADC Therapeutics, Celgene, Kyowa, Portola, Seattle Genetics, and Takeda and funds for research support from Celgene, Seattle Genetics, and Takeda.

Staff Disclosure

Staff

Terrence Fagan,

Associate Scientific Director

Terrence Fagan has no relevant conflicts of interest to report.

Gordon Kelley,

Clinical Editor
Clinical Care Options, LLC

Gordon Kelley has no relevant conflicts of interest to report.

Kevin Obholz, PhD

Editorial Director, Hematology/Oncology

Kevin Obholz, PhD, has no relevant conflicts of interest to report.

Timothy A. Quill, PhD

Senior Managing Editor

Timothy A. Quill, PhD, has no relevant conflicts of interest to report.

June Wasserstrom,

Director, CME Program Development

June Wasserman has no relevant conflicts of interest to report.